News and Analysis | Published:

Microglia-targeted candidates push the Alzheimer drug envelope

Nature Reviews Drug Discovery volume 17, pages 303305 (2018) | Download Citation

Denali Therapeutics is taking a swing at neuroinflammation with a first-in-man trial of a RIPK1 inhibitor, while the company and others search for ways to target microglial biology more precisely.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

About this article

Publication history




  1. Search for Asher Mullard in:

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing